BX Swiss TOP 30 CHF
1.268,93
PKT
-17,93
PKT
-1,39
%
Werbung
Analysen zu BX Swiss TOP 30 CHF-Werten
Datum | Rating | Analyst | |
---|---|---|---|
17.02.12 | ABB (Asea Brown Boveri) halten | Independent Research GmbH | |
16.02.12 | Swisscom buy | Société Générale Group S.A. (SG) | |
16.02.12 | Nestlé hold | ING | |
16.02.12 | Zurich Insurance buy | Sarasin Research | |
16.02.12 | Givaudan neutral | Sarasin Research | |
15.02.12 | Swisscom neutral | Sarasin Research | |
15.02.12 | Swiss Re equal-weight | Morgan Stanley | |
14.02.12 | UBS underperform | Exane-BNP Paribas SA | |
14.02.12 | UBS underperform | Exane-BNP Paribas SA | |
14.02.12 | Roche neutral | Citigroup Corp. | |
14.02.12 | Geberit halten | Öko Invest | |
14.02.12 | UBS overweight | HSBC | |
14.02.12 | UBS overweight | HSBC | |
13.02.12 | Zurich Insurance neutral | UBS AG | |
13.02.12 | ABB (Asea Brown Boveri) buy | ING | |
13.02.12 | UBS neutral | UBS AG | |
13.02.12 | Zurich Insurance buy | ING | |
10.02.12 | UBS halten | Independent Research GmbH | |
10.02.12 | UBS underperform | Exane-BNP Paribas SA | |
10.02.12 | UBS neutral | Nomura | |
10.02.12 | UBS hold | Société Générale Group S.A. (SG) | |
10.02.12 | UBS sector perform | RBC Capital Markets | |
10.02.12 | Swisscom buy | Société Générale Group S.A. (SG) | |
09.02.12 | Zurich Insurance neutral | J.P. Morgan Cazenove | |
09.02.12 | UBS hold | Commerzbank Corp. & Markets | |
09.02.12 | UBS outperform | Macquarie Research | |
09.02.12 | UBS sell | Deutsche Bank AG | |
09.02.12 | UBS outperform | RBC Capital Markets | |
08.02.12 | Holcim hold | Deutsche Bank AG | |
08.02.12 | Holcim hold | Deutsche Bank AG | |
08.02.12 | Zurich Insurance buy | Deutsche Bank AG | |
08.02.12 | UBS hold | Société Générale Group S.A. (SG) | |
08.02.12 | UBS buy | Nomura | |
08.02.12 | Roche halten | Hamburger Sparkasse AG (Haspa) | |
08.02.12 | UBS overweight | Morgan Stanley | |
08.02.12 | UBS verkaufen | Independent Research GmbH | |
07.02.12 | UBS neutral | WestLB AG | |
07.02.12 | Zurich Insurance neutral | J.P. Morgan Cazenove | |
07.02.12 | UBS neutral | Sarasin Research | |
07.02.12 | Novartis underperform | Banc of America Securities-Merrill Lynch |